How Long Does Wegovy Stay in Your System? [2026]

The Exact Product and Its Labeled Pharmacokinetics

Wegovy contains semaglutide. The Ozempic injection label describes an approximately one-week half-life and about five weeks in circulation after the last dose. The current Wegovy label describes about five to seven weeks after the last 2.4/7.2-mg injection or 25-mg oral dose. A shared ingredient does not make these products’ doses, devices, storage, indications or missed-dose instructions identical.

Ozempic injection reaches steady-state exposure after about four to five weeks of weekly dosing. This is exposure at a continuing dose, not complete elimination after one week or a guarantee that every clinical endpoint peaks after four weeks. Oral semaglutide also has a long elimination half-life despite daily administration; formulation-specific absorption, strengths and instructions remain important.

Elimination Estimates and What They Cannot Predict

A half-life describes an approximate decline during elimination, not an injected syringe volume instantly becoming the same number of milligrams in blood. Absorption takes time, and repeated dosing produces accumulation. The following illustration starts from a post-absorption reference level, assumes no further dose and does not include individual variability:

Repeated weekly dosing changes the starting exposure after the final dose; it does not by itself establish a new, longer elimination half-life. A fraction in this model cannot identify an individual’s appetite, glucose, weight, side-effect or laboratory timeline.

Kidney, Liver and Medicine Interactions

The Ozempic injection label does not recommend dose adjustment solely for renal impairment, including kidney failure, or hepatic impairment. Its PK analyses do not show a clinically meaningful age or renal-impairment effect. Exposure decreases with increasing body weight, but that is not a home weight-based dosing or elimination formula. Check the actual formulation’s label rather than inventing an eGFR-to-half-life chart.

Semaglutide is metabolized through peptide cleavage and fatty-acid beta-oxidation; related material is excreted in urine and feces, with about 3% of the dose excreted intact in urine in the injection label. It is not simply an unchanged drug cleared by the kidneys or governed by a generic CYP3A4 inhibitor/inducer rule. Dehydration-related kidney injury remains a risk despite the absence of a renal dose adjustment. Oral-medicine absorption and insulin/sulfonylurea hypoglycemia risks require product-specific review.

Missed Doses and Restarting

For Wegovy injection, the missed-dose instructions depend on time until the next scheduled dose: take it if the next dose is more than two days (48 hours) away; skip it when less than two days remain. Clarify uncertain boundary timing with the pharmacist. After two or more consecutive missed injections, the label allows resuming as scheduled or, if needed, reinitiating escalation to reduce GI effects; the prescriber should select the plan. Oral Wegovy missed-dose instructions are separate.

Procedures and Switching Treatment

Before anesthesia or deep sedation, tell the team the exact medicine, dose, escalation stage, last administration and current GI symptoms. The 2024 multisociety guidance supports individualized planning: lower-risk patients may continue, while escalation, higher doses, symptoms or other delayed-emptying conditions may call for extra measures such as a liquid-only diet for at least 24 hours, ultrasound, an altered anesthesia plan or postponement of elective care. Protocols differ; follow the procedure team’s actual instructions.

The guidance acknowledges uncertainty about the optimal hold interval when holding is chosen. A universal 1–2-week stop, specialty-specific timetable or promise that a washout prevents aspiration is not established. Emergency care should receive the last-dose information promptly. Restarting depends on recovery, usual intake, symptoms, interruption length and a prescriber’s plan, not an automatic 1–4-week postoperative rule or return to the prior dose.

A half-life does not choose the next product, starting dose or transition date. Zepbound and Wegovy labeling advise against coadministration with other GLP-1 receptor agonists or other products containing the same active ingredient. Do not assume same-day overlap is routinely safe, or that residual drug guarantees glucose coverage for weeks. Review the indication, other medicines, tolerability and monitoring plan with the prescriber when switching to another GLP-1 medicine or another drug class.

Appetite, Glucose and Weight After Stopping

Appetite, glucose and GI symptoms may change as exposure falls, but no universal day-by-day return-to-baseline clock is established. HbA1c reflects recent months of glucose exposure rather than an instant reading, and diabetes control may deteriorate before a calculated washout. Follow the monitoring plan and seek advice for meaningful changes rather than waiting two to four weeks.

Randomized STEP 4 studied 803 adults with overweight or obesity without diabetes who completed a 20-week subcutaneous semaglutide run-in: during the next 48 weeks, continued 2.4-mg weekly treatment changed weight by −7.9% versus +6.9% after withdrawal. Both groups continued lifestyle intervention. These label-reported findings support maintenance benefit and the possibility of regain; they are not a fixed personal regain percentage, blame for lifestyle failure or proof of unlimited safety. Returning appetite or weight alone does not prove addiction or permanent metabolic damage.

Pregnancy Planning and Drug Testing

For planned pregnancy, semaglutide labeling directs stopping at least two months beforehand because of its long washout. A two-week, four-week or calculated five-half-life interval is not a substitute. For weight management, Wegovy should be discontinued when pregnancy is recognized; other indication-specific risk-benefit decisions and diabetes treatment need coordinated obstetric and prescribing care. Oral SNAC-containing formulations have separate breastfeeding considerations; injection data should not be transferred automatically.

Testing depends on the panel and assay. Semaglutide and tirzepatide are not listed in the specific DOT urine panel in 49 CFR 40.85; that is not a guarantee about every employer, court, hospital or research test, or every cause of a positive result. Ask what the laboratory measures and use the appropriate medical-review disclosure process.

The WADA 2026 Monitoring Program lists markers of semaglutide and tirzepatide in and out of competition. Monitoring is distinct from prohibition. Athletes should check their sport’s current rules and medication process. Targeted assays and their detection limits differ from routine screening; a half-life calculation cannot promise a negative test or fixed detection window.